



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/686,619	10/17/2003	Margot Mary O'Toole	WYE-029	9490

54623 7590 04/23/2007
KIRKPATRICK & LOCKHART PRESTON GATES ELLIS LLP
STATE STREET FINANCIAL CENTER
ONE LINCOLN STREET
BOSTON, MA 02111-2950

EXAMINER

SALMON, KATHERINE D

ART UNIT	PAPER NUMBER
----------	--------------

1634

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	04/23/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/686,619

Applicant(s)

O'TOOLE ET AL.

Examiner

Katherine Salmon

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 08 March 2007.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1, 2, 4, 5, 8 and 22 is/are pending in the application.
- 4a) Of the above claim(s) 4 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-2, 5, 8, 22 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/08/2007 has been entered.

2. Currently Claims 1-2, 4-5, 8, and 22 are pending. Claims 3, 6-7, 9-21 have been canceled. Claim 4 has been withdrawn. Claims 1-2, 5, 8, 22 are currently under examination.

3. The following rejections are reiterated. Response to arguments follows.

Withdrawn Rejections

4. The rejection of Claims under 35 USC 112/second made in section 7 of the previous office.

Rejections Necessitated by Amendment

Claim Rejections - 35 USC § 112-Scope of Enablement

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1-2, 4-5, 8, and 22 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for

A method of identifying an increased likelihood of lupus nephritis in a mouse, the method comprising the steps of:

- a) obtaining a kidney sample from a control mouse and a mouse of interest
- b) detecting an expression level of the midkine mRNA transcript in the kidney sample of the control mouse and the mouse of interest
- c) comparing the midkine mRNA transcript level of the control mouse and the mouse of interest, wherein an increased expression level of the midkine mRNA transcript level of the mouse of interest relative to the expression level of the midkine mRNA transcript level indicates that the mouse of interest has an increased likelihood of lupus nephritis.

does not reasonably provide enablement for methods to diagnose lupus nephritis (LN) in mouse or human by detecting an elevated expression level of midkine gene. The specification does not enable any person skilled in the art to which it

Art Unit: 1634

pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The following factors have been considered in formulating this rejection (*In re Wands*, 858F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988): the breadth of the claims, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability of the art, the amount of direction or guidance presented, the presence or absence of working examples of the invention and the quantity of experimentation necessary.

Breadth of the Claims

The claims are broadly drawn to diagnosing lupus nephritis in a human or a mouse comprising detecting the expression level of midkine gene in a kidney sample wherein an elevated expression level indicates an increased likelihood of lupus nephritis. The claims are broadly drawn to both human and mouse.

The invention is in a class of inventions that the CAFC has characterized as "the unpredictable arts such as chemistry and biology" (*Mycolgen Plant Sci., Inc. v Monsanto Co.*, 243 F.3d 1316, 1330 (Federal Circuit 2001)).

Teachings in the Specification

The specification teaches systematic lupus erythematosus (SLE) is an autoimmune disease that has diverse and variable clinical manifestations that range from skin rash and joint pain that can show spontaneous remissions to severe kidney

Art Unit: 1634

disease that may result in renal failure, otherwise known as lupus nephritis (LN).

Midkine (MDK) has several functions including neural-glial interactions in brain development, inflammation, tumor and angiogenesis, and anti-apoptotic activities (specification, pages 14-19). The specification asserts that midkine is a marker for SLE or LN, and its expression can be utilized as a diagnostic for said diseases (page 4).

The specification concludes "MDK has not previously been associated with SLE and LN.....While mouse models were used for the initial differentiation expression analysis, it is well-appreciated that animal models can be interpreted to reflect expression levels from human subjects as well. The present invention...encompasses human MDK" (page 22). The specification further asserts "without limitation as to mechanism, the present invention is based in part on the principle that modulation of the expression of the MDK gene expression may ameliorate SLE/LN, when they are expressed at levels similar or substantially similar to normal non-diseased tissues" (page 23).

The specification discloses working examples of the isolation of RNA from kidney samples of several different mouse models of lupus that ranged in age of five months to 8, 16, 20 weeks of age, thus representing early, intermediate, and late stages of lupus, and control mice of the same age range. The working examples disclose that after the isolation of kidney tissues from said mice, RNA was isolated and cDNA was synthesized, and then the samples were analyzed with Affymetrix Mu11KsubA and Mu11KsubB microarrays. Statistical analysis was subsequently performed, and TaqMan assays were performed on genes of interest (pages 13-14 and 78-82).

Art Unit: 1634

State of the Prior Art

Kotzin et al. teaches (Cell, 1996, Vol. 85, pages 303-306) the underlying cause of lupus has yet to be determined as environmental factors such as sun exposure, viral or bacterial infections, hormonal and drug treatments, and genetic contributions play a role in the manifestation of the disease (Kotzin, page 305). Kotzin teaches several animal models have been used to study lupus, however, due to the complex nature of the disease, "even when one animal model and one phenotype is considered, the genetic basis of lupus-like disease is remarkably complex, involving contributions from multiple genes in addition to class II MHC....Furthermore, it seems likely that different genetic contributions are operative in different animal models (and therefore in different patients), even when the same phenotype is being followed" (page 305). Kotzin further teaches mouse models are used to study the genetic causes of lupus, and to predict human genes that are associated with said disease since mouse and human genes are homologous (Journal of Clinical Investigation, 1997, Vol.99, No. 4, pages 557-558). However, as stated above, environmental factors and phenotypic expression of lupus have considerable variation, and since the environment conditions are controlled for animal studies and the animal models are bred to have uniform lupus symptoms, it is unclear if results from animal studies can be applicable to humans. Kotzin teaches, "disease phenotype among mice in each cross is much more uniform compared to the relatively heterogeneous disease expression in patients. Especially in SLE, clinical manifestations and autoantibody production can be extremely diverse and variable, which is in part genetically based, and this variability can confound genetic studies" (Journal of Clinical Investigation, page 557). To ensure accurate predictions of the

Art Unit: 1634

results of mouse lupus models to humans “there should also be concern that an initial mapping in a complex trait reflects false positive readings....If true, this human locus...may not be in a region syntenic to the murine susceptibility locus, and linkage in the current human study would therefore represent quite a fortuitous finding,” and in order to ensure accurate results, large studies of human patients will need to be performed (Kotzin, Journal of Clinical Investigation, page 558).

The Relative Skill of Those in the Art

The level of skill in the art is deemed to be high.

The Predictability or Unpredictability of the Art and Degree of Experimentation

Moreover, as indicated by Kotzin et al., an animal model may not be an accurate representation of another animal's response to lupus. Genetic homology does not necessarily correlate to phenotypic expression. As mentioned previously, environmental factors play a role in the development of lupus, and it is unpredictable if a mouse, particularly in a controlled environment, will react in the same manner to environmental factors as humans.

Liu et al. (Clinical Immunology 2004 Vol. 112 p. 225) teaches that that correlation of genes to disease traits in mouse models is not indicative of correlation in humans. Liu et al. teaches that the gene expression profile of humans with autoimmune disease is not the same as the gene expression in a mouse model and in fact there is very little overlap in the gene expression profile of the two (Abstract). Liu et al. found that there

Art Unit: 1634

was no overlap between the differentially expressed genes between human and mouse data sets with regard to systemic lupus (p. 228 1st column 1st paragraph). Liu et al. teaches that their results show that murine models do not perfectly model corresponding human autoimmune diseases when gene expression profiles are considered (p. 229 2nd column last paragraph).

Morel et al. (PLOS Biology August 2004 Vol. 2 p. 1061) teaches that one cannot directly apply data obtained from animal models to human diseases (p. 1062 1st column last paragraph). Morel et al. teaches that human autoimmune diseases (which includes lupus) show extremely heterogeneous clinical presentation and that animal models only present a simplified version (p. 1062 1st column last paragraph). Morel et al. teaches the mouse model only provides a partial representation of the real biological complexity underlying the human disease (p. 1062 1st column last paragraph). Morel et al. teaches that extrapolation from animal models to autoimmune patients are limited by the differences between the two immune systems (p. 1062 2nd column 1st paragraph).

Consequently, it is unpredictable if a mouse phenotypic expression of lupus will be similar to humans. Consequently, the skilled artisan would have to examine midkine's expression in As a result, the specification does not teach the person skilled in the art how to reasonably predict, without undue burden, SLE or LN by midkine expression levels in a biological sample of human.

Amount of Direction or Guidance Provided by the Specification

Though the specification provides working examples of mouse models with regard to the detection and correlation of elevated expression levels of

Art Unit: 1634

midkine gene, the specification has not provided sufficient guidance to extrapolate these results to human. Further the art teaches that correlations in mouse models are not sufficient to correlate expression in humans. The art also teaches that expression profiles of genes differ in humans afflicted with autoimmune disease and mouse models with autoimmune disease.

Therefore the specification has not provides sufficient guidance to one skilled in the art to correlate elevated midkine levels to lupus in humans. Further the skilled artisan would have to perform undue experimentation to correlate midkine levels with lupus in humans because the art teaches that correlations in mouse models cannot be extrapolated to humans without intervening experimental steps, which have no guarantee of success.

Working Example

The specification does not provide working examples of methods to diagnose lupus with midkine expression levels in human. The methods do not demonstrate the methodology can be used to predictably diagnose lupus with midkine mRNA in humans.

Conclusions

Case law has established that '(t)o be enabling, the specification of a patent must teach those skilled in the art how to make and use the full scope of the claimed invention without 'undue experimentation.'" In re Wright 990 F.2d 1557, 1561. In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) it was determined that '(t)he scope of the claims must bear a reasonable correlation to the scope of enablement

Art Unit: 1634

provided by the specification to persons of ordinary skill in the art". The amount of guidance needed to enable the invention is related to the amount of knowledge in the art as well as the predictability in the art. Furthermore, the Court in *Genentech Inc. v Novo Nordisk* 42 USPQ2d 1001 held that "(l)t is the specification, not the knowledge of one skilled in the art that must supply the novel aspects of the invention in order to constitute adequate enablement". In view of the high level of unpredictability in the art and lack of guidance provided by the specification and prior art, undue experimentation would be required to practice the claimed invention.

Response to Arguments

The reply traverses the rejection. The reply asserts that the specification provides working examples in mouse models demonstrating elevated expression in lupus-bearing or lupus-predisposed kidney samples using mouse models (p. 4 1st paragraph). The reply asserts that the mouse model is enabling for human samples because the mouse model is accepted in the scientific community as models for human lupus (p. 4 1st paragraph).

To be enabled for a method of diagnosing lupus nephritis in a human, the specification does not have to reduce to practice but must describe the method in a way that the skilled artisan could make and use the method without undue experimentation. The specification asserts correlation of expression of a mouse midkine gene with lupus. The specification asserts that the mouse gene and the human gene have "similar" homology. However, in order to make a correlation between a human gene and a

Art Unit: 1634

disease undue experimentation by the skilled artisan must be performed. The skilled artisan would need to determine if any variant of any fragment of the midkine gene would have the same level of expression in both mouse and human so as to be diagnostic for lupus. The skilled artisan would need to determine the necessary amino acids needed to define the midkine gene in both animals and determine if changes in the amino acids would have the same change in functionality in both animals. Further, the skilled artisan would also have to determine if population stratification would affect expression levels of the midkine gene in human.

Also, as shown in the art discussion above, the correlation of a gene expression in mouse cannot be extrapolated to humans. The art teaches that the mouse model has different gene expression profiles than humans and that the correlation of a disease to a gene in mouse models does not mean that the same association exists in human.

Conclusion


6. No Claims are allowed.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Katherine Salmon whose telephone number is (571) 272-3316. The examiner can normally be reached on Monday-Friday 8AM-430PM.

Art Unit: 1634

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Katherine Salmon
Examiner
Art Unit 1634


CARLA J. MYERS
PRIMARY EXAMINER